Sullivan Christopher Ryan 4
4 · Avalo Therapeutics, Inc. · Filed Mar 2, 2026
Research Summary
AI-generated summary of this filing
Avalo (AVTX) CFO Christopher Sullivan Receives 105,000-Share Option Award
What Happened
Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics (AVTX), was granted a derivative award on February 26, 2026: an award covering 105,000 shares (reported with a $0.00 price). The filing classifies this as an award/grant (transaction code A) of a stock option that vests over time rather than an open‑market purchase or sale.
Key Details
- Transaction date: 2026-02-26; Form 4 filed 2026-03-02 (timely filing).
- Transaction type/code: Award/Grant (A) — derivative security reported.
- Amount granted: 105,000 shares (derivative). Price reported: $0.00.
- Vesting: 25% vests on Feb 26, 2027; remaining balance vests in equal monthly installments over the following 3 years, subject to continued service (per footnote).
- Shares owned after transaction: Not specified in the provided excerpt.
- No immediate sale or cashless exercise reported — this is a time‑based equity award, not a market trade.
Context
This grant is a compensatory equity award that vests over multiple years, meaning Sullivan must remain employed for the award to convert into owned shares. Such awards are common for executive retention and do not represent an immediate purchase or sale in the open market.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-02-26+105,000→ 105,000 totalExercise: $17.64Exp: 2036-02-26→ Common Stock (105,000 underlying)
Footnotes (1)
- [F1]The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.